Galectin Therapeutics (GALT) Change in Cash (2010 - 2026)

Galectin Therapeutics' Change in Cash history runs 17 years deep, the most recent figure standing at -$3.6 million for Q1 2026.

• In Q1 2026, Change in Cash rose 53.06% year-over-year to -$3.6 million; the TTM figure through Mar 2026 stood at $6.7 million (up 141.43% YoY), while the FY2025 annual figure was $2.6 million, up 124.67% from the prior year.
• Change in Cash was -$3.6 million for Q1 2026 at Galectin Therapeutics, down from $6.2 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $6.3 million in Q2 2025 to a low of -$11.9 million in Q4 2024.
• Historically, Change in Cash has averaged -$1.5 million across 5 years, with a median of -$793000.0 in 2023.
• Biggest YoY gain for Change in Cash was 1123.35% in 2024; the steepest drop was 325.37% in 2024.
• A 5-year view of Change in Cash shows it stood at $2.8 million in 2022, then surged by 91.89% to $5.3 million in 2023, then sank by 325.37% to -$11.9 million in 2024, then jumped by 151.88% to $6.2 million in 2025, then tumbled by 158.26% to -$3.6 million in 2026.
• The last three Change in Cash figures came in at -$3.6 million (Q1 2026), $6.2 million (Q4 2025), and -$2.2 million (Q3 2025), per Business Quant data.